Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

Free Abstracts

  Head and Neck Cancer

  Free Subscription


Articles published in J Clin Endocrinol Metab

Retrieve available abstracts of 88 articles:
HTML format
Text format



Single Articles


    April 2018
  1. TRAN B DR., Roshan D Mr., Abraham E Dr., Wang L Dr., et al
    An Analysis of The American Joint Committee on Cancer 8th Edition T Staging System for Papillary Thyroid Carcinoma.
    J Clin Endocrinol Metab. 2018 Apr 16. pii: 4970148. doi: 10.1210/jc.2017-02551.
    PubMed     Text format     Abstract available


    February 2018
  2. WASSERMAN JD, Sabbaghian N, Fahiminiya S, Chami R, et al
    DICER1 mutations are frequent in adolescent-onset papillary thyroid carcinoma.
    J Clin Endocrinol Metab. 2018 Feb 21. pii: 4893697. doi: 10.1210/jc.2017-02698.
    PubMed     Text format     Abstract available


  3. SAMUELS SL, Surrey LF, Hawkes CP, Amberge M, et al
    Characteristics of Follicular Variant Papillary Thyroid Carcinoma in a Pediatric Cohort.
    J Clin Endocrinol Metab. 2018 Feb 8. pii: 4844750. doi: 10.1210/jc.2017-02454.
    PubMed     Text format     Abstract available


    January 2018
  4. GIORDANO TJ, Haugen B, Sherman SI, Shah MH, et al
    Pioglitazone Therapy of PAX8-PPARgamma Fusion Protein Thyroid Carcinoma.
    J Clin Endocrinol Metab. 2018 Jan 24. pii: 4822913. doi: 10.1210/jc.2017-02533.
    PubMed     Text format     Abstract available


    December 2017
  5. RITTER A, Bachar G, Hirsch D, Benbassat C, et al
    Natural History of Contralateral Nodules after Lobectomy in Patients with Papillary Thyroid Carcinoma.
    J Clin Endocrinol Metab. 2017 Dec 12. pii: 4731740. doi: 10.1210/jc.2017-01616.
    PubMed     Text format     Abstract available


  6. VAN DER TUIN K, Tops CMJ, Adank MA, Cobben JM, et al
    CDC73-Related Disorders: Clinical Manifestations and Case Detection in Primary Hyperparathyroidism.
    J Clin Endocrinol Metab. 2017;102:4534-4540.
    PubMed     Text format     Abstract available


    November 2017
  7. HE H, Li W, Liyanarachchi S, Wang Y, et al
    The role of NRG1 in the predisposition to papillary thyroid carcinoma.
    J Clin Endocrinol Metab. 2017 Nov 7. doi: 10.1210/jc.2017-01798.
    PubMed     Text format     Abstract available


  8. MAZZIOTTI G, Formenti AM, Frara S, Olivetti R, et al
    HIGH PREVALENCE OF RADIOLOGICAL VERTEBRAL FRACTURES IN WOMEN ON TSH-SUPPRESSIVE THERAPY FOR THYROID CARCINOMA.
    J Clin Endocrinol Metab. 2017 Nov 7. doi: 10.1210/jc.2017-01986.
    PubMed     Text format     Abstract available


  9. CASEY RT, Warren AY, Martin JE, Challis BG, et al
    Clinical and Molecular Features of Renal and Pheochromocytoma/Paraganglioma Tumor Association Syndrome (RAPTAS): Case Series and Literature Review.
    J Clin Endocrinol Metab. 2017;102:4013-4022.
    PubMed     Text format     Abstract available


    October 2017

  10. CORRIGENDUM FOR Letter to the Editor: "Medullary Thyroid Carcinoma in MEN2A: ATA Moderate- or High-Risk RET Mutations Do Not Predict Disease Aggressiveness".
    J Clin Endocrinol Metab. 2017 Oct 24. doi: 10.1210/jc.2017-02312.
    PubMed     Text format    


  11. ANGELL TE, Vyas C, Medici M, Wang Z, et al
    Differential Growth Rates of Benign versus Malignant Thyroid Nodules.
    J Clin Endocrinol Metab. 2017 Oct 12. doi: 10.1210/jc.2017-01832.
    PubMed     Text format     Abstract available


  12. PRASONGSOOK N, Kumar A, Chintakuntlawar AV, Foote RL, et al
    Survival in Response to Multimodal Therapy in Anaplastic Thyroid Cancer.
    J Clin Endocrinol Metab. 2017 Oct 5. doi: 10.1210/jc.2017-01180.
    PubMed     Text format     Abstract available


    September 2017
  13. VOSS RK, Grubbs EG
    Response to Letter: "Medullary Thyroid Carcinoma in MEN2A: ATA Moderate- or High-Risk RET Mutations Do Not Predict Disease Aggressiveness".
    J Clin Endocrinol Metab. 2017;102:3559.
    PubMed     Text format    


  14. CASTINETTI F, Whollk N
    Letter to the Editor: "Medullary Thyroid Carcinoma in MEN2A: ATA Moderate- or High-Risk RET Mutations Do Not Predict Disease Aggressiveness".
    J Clin Endocrinol Metab. 2017;102:3557-3558.
    PubMed     Text format    


  15. COTE GJ, Evers C, Hu MI, Grubbs EG, et al
    Prognostic Significance of Circulating RET M918T Mutated Tumor DNA in Patients With Advanced Medullary Thyroid Carcinoma.
    J Clin Endocrinol Metab. 2017;102:3591-3599.
    PubMed     Text format     Abstract available


  16. VIOLA D, Giani C, Mazzeo S, Ugolini C, et al
    KIF5B/RET Rearrangement in a Carcinoma of the Thyroid Gland: A Case Report of a Fatal Disease.
    J Clin Endocrinol Metab. 2017;102:3091-3096.
    PubMed     Text format     Abstract available


    August 2017
  17. DOS REIS MB, Barros-Filho MC, Marchi FA, Beltrami CM, et al
    Prognostic classifier based on genome-wide DNA methylation profiling in well-differentiated thyroid tumors.
    J Clin Endocrinol Metab. 2017 Aug 16. doi: 10.1210/jc.2017-00881.
    PubMed     Text format     Abstract available


    June 2017
  18. SZCZEPANEK-PARULSKA E, Zybek-Kocik A, Wartofsky L, Ruchala M, et al
    Thyroid hemiagenesis: incidence, clinical significance and genetic background.
    J Clin Endocrinol Metab. 2017 Jun 28. doi: 10.1210/jc.2017-00784.
    PubMed     Text format     Abstract available


  19. ROSSFELD KK, Justiniano SE, Ding H, Gong L, et al
    Biological evaluation of a novel fluorescent-imaging agent for medullary thyroid cancer in an orthotopic model.
    J Clin Endocrinol Metab. 2017 Jun 7. doi: 10.1210/jc.2017-00573.
    PubMed     Text format     Abstract available


  20. WANG F, Yu X, Shen X, Zhu G, et al
    The Prognostic Value of Tumor Multifocality in Clinical Outcomes of Papillary Thyroid Cancer.
    J Clin Endocrinol Metab. 2017 Jun 5. doi: 10.1210/jc.2017-00277.
    PubMed     Text format     Abstract available


  21. MATHIESEN JS, Habra MA, Bassett JHD, Choudhury SM, et al
    Risk Profile of the RET A883F Germline Mutation: An International Collaborative Study.
    J Clin Endocrinol Metab. 2017;102:2069-2074.
    PubMed     Text format     Abstract available


    May 2017
  22. LEE JJ, Wang TY, Liu CL, Chien MN, et al
    Dipeptidyl peptidase IV as a prognostic marker and therapeutic target in papillary thyroid carcinoma.
    J Clin Endocrinol Metab. 2017 May 26. doi: 10.1210/jc.2017-00346.
    PubMed     Text format     Abstract available


  23. VOSS RK, Feng L, Lee JE, Perrier ND, et al
    Medullary Thyroid Carcinoma in MEN2A: ATA Moderate or High-Risk RET Mutations Do Not Predict Disease Aggressiveness
    J Clin Endocrinol Metab. 2017 May 9. doi: 10.1210/jc.2017-00317.
    PubMed     Text format     Abstract available


  24. IMAIZUMI M, Ohishi W, Nakashima E, Sera N, et al
    Thyroid dysfunction and autoimmune thyroid diseases among atomic-bomb survivors exposed in childhood.
    J Clin Endocrinol Metab. 2017 May 1. doi: 10.1210/jc.2017-00102.
    PubMed     Text format     Abstract available


    April 2017
  25. PAPALEONTIOU M, Hughes DT, Guo C, Banerjee M, et al
    Population-Based Assessment of Complications following Surgery for Thyroid Cancer.
    J Clin Endocrinol Metab. 2017 Apr 28. doi: 10.1210/jc.2017-00255.
    PubMed     Text format     Abstract available


  26. WASSNER AJ, Della Vecchia M, Jarolim P, Feldman HA, et al
    Prevalence and Significance of Thyroglobulin Antibodies in Pediatric Thyroid Cancer.
    J Clin Endocrinol Metab. 2017 Apr 10. doi: 10.1210/jc.2017-00286.
    PubMed     Text format     Abstract available


    March 2017
  27. CAHOON EK, Nadirov EA, Polanskaya ON, Yauseyenka VV, et al
    Risk of thyroid nodules in residents of Belarus exposed to Chernobyl fallout as children and adolescents.
    J Clin Endocrinol Metab. 2017 Mar 22. doi: 10.1210/jc.2016-3842.
    PubMed     Text format     Abstract available


  28. LUBIN JH, Adams MJ, Shore R, Holmberg E, et al
    Thyroid cancer following childhood low dose radiation exposure: a pooled analysis of nine cohorts.
    J Clin Endocrinol Metab. 2017 Mar 8. doi: 10.1210/jc.2016-3529.
    PubMed     Text format     Abstract available


  29. MELO M, Gaspar da Rocha A, Batista R, Vinagre J, et al
    TERT, BRAF and NRAS in primary thyroid cancer and metastatic disease.
    J Clin Endocrinol Metab. 2017 Mar 6. doi: 10.1210/jc.2016-2785.
    PubMed     Text format     Abstract available


  30. KWON H, Oh HS, Kim M, Park S, et al
    Active Surveillance for Patients with Papillary Thyroid Microcarcinoma: A Single Center's Experience in Korea.
    J Clin Endocrinol Metab. 2017 Mar 3. doi: 10.1210/jc.2016-4026.
    PubMed     Text format     Abstract available


    February 2017
  31. KIM TH, Ki CS, Kim HS, Kim K, et al
    Refining dynamic risk stratification and prognostic groups for differentiated thyroid cancer with TERT promoter mutations.
    J Clin Endocrinol Metab. 2017 Feb 28. doi: 10.1210/jc.2016-3434.
    PubMed     Text format     Abstract available


  32. KHAN NE, Bauer AJ, Schultz KA, Doros L, et al
    Quantification of thyroid cancer and multinodular goiter risk in the DICER1 syndrome: a family-based cohort study.
    J Clin Endocrinol Metab. 2017 Feb 2. doi: 10.1210/jc.2016-2954.
    PubMed     Text format     Abstract available


    January 2017
  33. CHOKSI P, Papaleontiou M, Guo C, Worden F, et al
    Skeletal Complications and Mortality in Thyroid Cancer: A Population-Based Study.
    J Clin Endocrinol Metab. 2017 Jan 25. doi: 10.1210/jc.2016-3906.
    PubMed     Text format     Abstract available


  34. PARK S, Jeon MJ, Song E, Oh HS, et al
    Clinical Features of Early and Late Postoperative Hypothyroidism after Lobectomy.
    J Clin Endocrinol Metab. 2017 Jan 11. doi: 10.1210/jc.2016-3597.
    PubMed     Text format     Abstract available


    December 2016
  35. NIES M, Klein Hesselink MS, Huizinga GA, Sulkers E, et al
    Long-term Quality of Life in Adult Survivors of Pediatric Differentiated Thyroid Carcinoma.
    J Clin Endocrinol Metab. 2016 Dec 21:jc20162246. doi: 10.1210/jc.2016-2246.
    PubMed     Text format     Abstract available


  36. BAGHERI-YARMAND R, Williams MD, Grubbs EG, Gagel RF, et al
    ATF4 Targets RET for Degradation and is a Candidate Tumor Suppressor Gene in Medullary Thyroid Cancer.
    J Clin Endocrinol Metab. 2016 Dec 9:jc20162878.
    PubMed     Text format     Abstract available


  37. MATRONE A, Gambale C, Piaggi P, Viola D, et al
    Postoperative thyroglobulin and neck ultrasound in the risk re-stratification and decision to perform 131I ablation.
    J Clin Endocrinol Metab. 2016 Dec 8:jc20162860.
    PubMed     Text format     Abstract available


    November 2016
  38. SCHNEIDER TC, de Wit D, Links TP, van Erp NP, et al
    Everolimus in patients with advanced follicular-derived thyroid cancer; results of a phase II clinical trial.
    J Clin Endocrinol Metab. 2016 Nov 21:jc20162525.
    PubMed     Text format     Abstract available


  39. EHLERS M, Kuebart A, Hautzel H, Enczmann J, et al
    Epitope-specific antitumor immunity suppresses tumor spread in papillary thyroid cancer.
    J Clin Endocrinol Metab. 2016 Nov 18:jc20162469.
    PubMed     Text format     Abstract available


  40. MAROTTA V, Sciammarella C, Capasso M, Testori A, et al
    Germline polymorphisms of the VEGF-pathway predict recurrence in non-advanced differentiated thyroid cancer.
    J Clin Endocrinol Metab. 2016 Nov 16:jc20162555.
    PubMed     Text format     Abstract available


  41. SUNG TY, Jeon MJ, Lee YH, Lee YM, et al
    Initial and Dynamic Risk Stratification of Pediatric Patients with Differentiated Thyroid Cancer.
    J Clin Endocrinol Metab. 2016 Nov 3:jc20162666.
    PubMed     Text format     Abstract available


    October 2016
  42. MOON JH, Kim KM, Oh TJ, Choi SH, et al
    The effect of TSH-suppression on vertebral trabecular bone scores in patients with differentiated thyroid carcinoma.
    J Clin Endocrinol Metab. 2016 Oct 18:jc20162740.
    PubMed     Text format     Abstract available


  43. WANG W, Kang H, Zhao Y, Min I, et al
    Targeting autophagy sensitizes BRAF-mutant thyroid cancer to vemurafenib.
    J Clin Endocrinol Metab. 2016 Oct 18:jc20161999.
    PubMed     Text format     Abstract available


  44. TALLINI G, Tuttle RM, Ghossein RA
    THE HISTORY OF THE FOLLICULAR VARIANT OF PAPILLARY THYROID CARCINOMA.
    J Clin Endocrinol Metab. 2016 Oct 12:jc20162976.
    PubMed     Text format     Abstract available


  45. ZHANG Y, Sui F, Ma J, Ren X, et al
    Positive Feedback Loops between NrCAM and Major Signaling Pathways Contribute to Thyroid Tumorigenesis.
    J Clin Endocrinol Metab. 2016 Oct 12:jc20161677.
    PubMed     Text format     Abstract available


  46. HWANGBO Y, Kim JM, Park YJ, Lee EK, et al
    Long-term Recurrence of Small Papillary Thyroid Cancer and Its Risk Factors in a Korean Multicenter Study.
    J Clin Endocrinol Metab. 2016 Oct 12:jc20162287.
    PubMed     Text format     Abstract available


    September 2016
  47. KAKARMATH S, Heller HT, Alexander CA, Cibas ES, et al
    Clinical, Sonographic, and Pathologic Characteristics of RAS-positive versus BRAF-positive Thyroid Carcinoma.
    J Clin Endocrinol Metab. 2016 Sep 30:jc20162620.
    PubMed     Text format     Abstract available


  48. XU JY, Murphy WA Jr, Milton DR, Jimenez C, et al
    Bone Metastases and Skeletal-Related Events in Medullary Thyroid Carcinoma.
    J Clin Endocrinol Metab. 2016 Sep 23:jc20162815.
    PubMed     Text format     Abstract available


  49. KIM SW, Song SH, Lee HS, Noh WJ, et al
    Intraoperative Real-Time Localization of Normal Parathyroid Glands with Autofluorescence Imaging.
    J Clin Endocrinol Metab. 2016 Sep 20:jc20162558.
    PubMed     Text format     Abstract available


  50. CHEREAU N, Giudicelli X, Pattou F, Lifante JC, et al
    Diffuse sclerosing variant of papillary thyroid carcinoma is associated with aggressive histopathological features and a poor outcome: Results of a large multicentric study.
    J Clin Endocrinol Metab. 2016 Sep 14:jc20162341.
    PubMed     Text format     Abstract available


  51. UCHINO S, Ishikawa H, Miyauchi A, Hirokawa M, et al
    Age- and Gender-Specific Risk of Thyroid Cancer in Patients with Familial Adenomatous Polyposis.
    J Clin Endocrinol Metab. 2016 Sep 13:jc20162043.
    PubMed     Text format     Abstract available


    August 2016
  52. YU XU J, Handy B, Michaelis CL, Waguespack SG, et al
    Detection and Prognostic Significance of Circulating Tumor Cells in Patients with Metastatic Thyroid Cancer.
    J Clin Endocrinol Metab. 2016 Aug 30:jc20162567.
    PubMed     Text format     Abstract available


  53. TORREGROSSA L, Viola D, Sensi E, Giordano M, et al
    Papillary Thyroid Carcinoma With Rare exon 15 BRAF Mutation Has Indolent Behavior: A Single-Institution Experience.
    J Clin Endocrinol Metab. 2016 Aug 29:jc20161775.
    PubMed     Text format     Abstract available


  54. ROBINSON B, Schlumberger M, Wirth LJ, Dutcus CE, et al
    Characterization of Tumor Size Changes Over Time From the Phase 3 Study of Lenvatinib in Thyroid Cancer.
    J Clin Endocrinol Metab. 2016 Aug 22:jc20153989.
    PubMed     Text format     Abstract available


  55. CHOU CK, Chi SY, Huang CH, Chou FF, et al
    IRAK1, a Target of miR-146b, Reduces Cell Aggressiveness of Human Papillary Thyroid Carcinoma.
    J Clin Endocrinol Metab. 2016 Aug 17:jc20162276.
    PubMed     Text format     Abstract available


  56. HOLLINGSWORTH B, Senter L, Zhang X, Brock GN, et al
    Risk Factors of 131I-Induced Salivary Gland Damage in Thyroid Cancer Patients.
    J Clin Endocrinol Metab. 2016 Aug 17:jc20161605.
    PubMed     Text format     Abstract available


  57. PALERMO A, Mangiameli G, Tabacco G, Longo F, et al
    PTH(1-34) for the primary prevention of post-thyroidectomy hypocalcemia: the THYPOS trial.
    J Clin Endocrinol Metab. 2016 Aug 15:jc20162530.
    PubMed     Text format     Abstract available


  58. LY S, Frates MC, Benson CB, Peters HE, et al
    Features and outcome of autonomous thyroid nodules in children: 31 consecutive patients seen at a single center.
    J Clin Endocrinol Metab. 2016 Aug 8:jc20161779.
    PubMed     Text format     Abstract available


    July 2016
  59. LIYANARACHCHI S, Li W, Yan P, Bundschuh R, et al
    Genome-wide expression screening discloses long noncoding RNAs involved in thyroid carcinogenesis.
    J Clin Endocrinol Metab. 2016 Jul 26:jc20161991.
    PubMed     Text format     Abstract available


  60. LUO J, Hendryx M, Manson JE, Liang X, et al
    Hysterectomy, oophorectomy and risk of thyroid cancer.
    J Clin Endocrinol Metab. 2016 Jul 26:jc20162011.
    PubMed     Text format     Abstract available


    May 2016
  61. LAMARTINA L, Grani G, Biffoni M, Giacomelli L, et al
    Risk stratification of neck lesions detected sonographically during the follow-up of differentiated thyroid cancer.
    J Clin Endocrinol Metab. 2016 May 17:jc20161440.
    PubMed     Text format     Abstract available


    April 2016
  62. LAMARTINA L, Ippolito S, Danis M, Bidault F, et al
    Anti-angiogenic Tyrosine Kinase Inhibitors: occurrence and risk factors of hemoptysis in refractory thyroid cancer.
    J Clin Endocrinol Metab. 2016 Apr 15:jc20154391.
    PubMed     Text format     Abstract available


  63. BASTMAN JJ, Serracino HS, Zhu Y, Koenig MR, et al
    Tumor-infiltrating T Cells and the PD-1 Checkpoint Pathway in Advanced Differentiated and Anaplastic Thyroid Cancer.
    J Clin Endocrinol Metab. 2016 Apr 5:jc20154227.
    PubMed     Text format     Abstract available


    March 2016
  64. MOMESSO DP, Vaisman F, Yang SP, Bulzico DA, et al
    DYNAMIC RISK STRATIFICATION IN DIFFERENTIATED THYROID CANCER PATIENTS TREATED WITHOUT RADIOACTIVE IODINE.
    J Clin Endocrinol Metab. 2016 Mar 29:jc20154290.
    PubMed     Text format     Abstract available


  65. BURCH HB, Burman KD, Cooper DS, Hennessey JV, et al
    A 2015 Survey of Clinical Practice Patterns in the Management of Thyroid Nodules.
    J Clin Endocrinol Metab. 2016 Mar 25:jc20161155.
    PubMed     Text format     Abstract available


  66. KLEIN HESSELINK MS, Nies M, Bocca G, Brouwers AH, et al
    Pediatric differentiated thyroid carcinoma in the Netherlands: a nationwide follow-up study.
    J Clin Endocrinol Metab. 2016 Mar 10:jc20153290.
    PubMed     Text format     Abstract available


  67. KURIEN BT, Lane JT, Scofield RH
    Letter to the Editor: Getting to the True Values of Thyroglobulin and Anti-Thyroglobulin Antibodies.
    J Clin Endocrinol Metab. 2016;101:L38-9.
    PubMed     Text format    


  68. LATTEYER S, Klein-Hitpass L, Khandanpour C, Zwanziger D, et al
    A 6-Base Pair in Frame Germline Deletion in Exon 7 Of RET Leads to Increased RET Phosphorylation, ERK Activation, and MEN2A.
    J Clin Endocrinol Metab. 2016;101:1016-22.
    PubMed     Text format     Abstract available


  69. LADENSON PW
    Precision Medicine Comes to Thyroidology.
    J Clin Endocrinol Metab. 2016;101:799-803.
    PubMed     Text format     Abstract available


  70. LAZAR L, Lebenthal Y, Segal K, Steinmetz A, et al
    Pediatric thyroid cancer: postoperative classifications and response-to-initial-therapy as prognostic factors.
    J Clin Endocrinol Metab. 2016 Mar 1:jc20153960.
    PubMed     Text format     Abstract available


    February 2016
  71. AHN D, Ho Sohn J, Han Jeon J
    Hypothyroidism following hemithyroidectomy: incidence, risk factors, and clinical characteristics.
    J Clin Endocrinol Metab. 2016 Feb 22:jc20153997.
    PubMed     Text format     Abstract available


  72. BIKAS A, Schneider M, Desale S, Atkins F, et al
    Effects of Dosimetrically-Guided I-131 Therapy on Hematopoiesis in Patients with Differentiated Thyroid Cancer.
    J Clin Endocrinol Metab. 2016 Feb 22:jc20153544.
    PubMed     Text format     Abstract available


  73. YU Y, Zhang J, Lu G, Li T, et al
    Clinical relationship between IgG4-positive Hashimoto's thyroiditis and papillary thyroid carcinoma.
    J Clin Endocrinol Metab. 2016 Feb 11:jc20153783.
    PubMed     Text format     Abstract available


  74. FINKEL A, Liba L, Simon E, Bick T, et al
    Sub-clonality for BRAF mutation in papillary thyroid carcinoma is associated with earlier disease stage.
    J Clin Endocrinol Metab. 2016 Feb 2:jc20154031.
    PubMed     Text format     Abstract available


  75. ALVES TG, Kasamatsu TS, Yang JH, Meneghetti MC, et al
    Macrocalcitonin Is a Novel Pitfall in the Routine of Serum Calcitonin Immunoassay.
    J Clin Endocrinol Metab. 2016;101:653-8.
    PubMed     Text format     Abstract available


    January 2016
  76. YANG X, Liang J, Li T, Zhao T, et al
    Preablative stimulated thyroglobulin correlates to new therapy response system in differentiated thyroid cancer.
    J Clin Endocrinol Metab. 2016 Jan 20:jc20154016.
    PubMed     Text format     Abstract available


  77. LUO J, Phillips L, Liu S, Wactawski-Wende J, et al
    Diabetes, diabetes treatment and risk of thyroid cancer.
    J Clin Endocrinol Metab. 2016 Jan 13:jc20153901.
    PubMed     Text format     Abstract available


  78. CHENG W, Liu R, Zhu G, Wang H, et al
    Robust Thyroid Gene Expression and Radioiodine Uptake Induced by Simultaneous Suppression of BRAF V600E and Histone Deacetylase in Thyroid Cancer Cells.
    J Clin Endocrinol Metab. 2016 Jan 11:jc20153433.
    PubMed     Text format     Abstract available


  79. NISHIMOTO K, Seki T, Kurihara I, Yokota K, et al
    Case Report: Nodule Development From Subcapsular Aldosterone-Producing Cell Clusters Causes Hyperaldosteronism.
    J Clin Endocrinol Metab. 2016;101:6-9.
    PubMed     Text format     Abstract available


    November 2015
  80. SHI X, Liu R, Basolo F, Giannini R, et al
    Differential Clinicopathological Risk and Prognosis of Major Papillary Thyroid Cancer Variants.
    J Clin Endocrinol Metab. 2015 Nov 3:jc20152917.
    PubMed     Text format     Abstract available


    October 2015
  81. KWONG N, Medici M, Angell TE, Liu X, et al
    The Influence of Patient Age on Thyroid Nodule Formation, Multinodularity, and Thyroid Cancer Risk.
    J Clin Endocrinol Metab. 2015 Oct 14:jc20153100.
    PubMed     Text format     Abstract available


    September 2015
  82. BIBLE KC, Cote GJ, Demeure MJ, Elisei R, et al
    Correlative Studies in Clinical Trials: A Position Statement From the International Thyroid Oncology Group.
    J Clin Endocrinol Metab. 2015 Sep 29:jc20152818.
    PubMed     Text format     Abstract available


  83. ANGELL TE, Frates MC, Medici M, Liu X, et al
    Afirma Benign Thyroid Nodules Show Similar Growth to Cytologically Benign Nodules During Follow Up.
    J Clin Endocrinol Metab. 2015 Sep 9:jc20152658.
    PubMed     Text format     Abstract available


  84. AHN HY, Min HS, Yeo Y, Ma SH, et al
    Radioactive Iodine Therapy Did Not Significantly Increase the Incidence and Recurrence of Subsequent Breast Cancer.
    J Clin Endocrinol Metab. 2015;100:3486-93.
    PubMed     Text format     Abstract available


    August 2015
  85. PACELLA CM, Mauri G, Achille G, Barbaro D, et al
    Outcomes and Risk Factors for Complications of Laser Ablation for Thyroid Nodules. A Multicenter Study on 1531 Patients.
    J Clin Endocrinol Metab. 2015 Aug 14:jc20151964.
    PubMed     Text format     Abstract available


  86. NETZEL BC, Grebe SK, Carranza Leon BG, Castro MR, et al
    Thyroglobulin (Tg) Testing Revisited: Tg Assays, TgAb Assays, and Correlation of Results With Clinical Outcomes.
    J Clin Endocrinol Metab. 2015;100:E1074-83.
    PubMed     Text format     Abstract available


    July 2015
  87. BELOUSOV PV, Bogolyubova AV, Kim YS, Abrosimov AY, et al
    Serum Immunoproteomics Combined With Pathological Reassessment of Surgical Specimens Identifies TCP-1zeta Autoantibody As a Potential Biomarker in Thyroid Neoplasia.
    J Clin Endocrinol Metab. 2015 Jul 21:jc20144260.
    PubMed     Text format     Abstract available


  88. GIANI F, Vella V, Nicolosi ML, Fierabracci A, et al
    THYROSPHERES FROM NORMAL OR MALIGNANT THYROID TISSUE HAVE DIFFERENT BIOLOGIC, FUNCTIONAL AND GENETIC FEATURES.
    J Clin Endocrinol Metab. 2015 Jul 7:JC20144163.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Head and Neck Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: